Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

June 02, 2015 7:03 AM ET


Company Overview of Provectus Biopharmaceuticals, Inc.

Company Overview

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. The company is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, it develops PH-10 for the treatment of ...

7327 Oak Ridge Highway

Suite A

Knoxville, TN 37931

United States

Founded in 2002

4 Employees





Key Executives for Provectus Biopharmaceuticals, Inc.

Chairman, Chief Executive Officer, Chief Executive Officer of Xantech and Director of Xantech
Age: 62
Total Annual Compensation: $500.0K
President, Director, President of Xantech and Director of Xantech
Age: 56
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corporate Treasurer and Secretary
Age: 55
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice President
Age: 51
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

Provectus Biopharmaceuticals, Inc. Key Developments

Provectus Biopharmaceuticals, Inc. Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, Sinopharm a-Think Pharmaceutical

Provectus Biopharmaceuticals, Inc. announced that it had extended for an additional 60 days its Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co. Ltd. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015. The original MOU was signed in August 2014, and since then, the parties have sought to enter into a definitive licensing agreement, subject to additional negotiation, due diligence, and any required regulatory and corporate approvals. The original MOU was to be in effect for 90 days, and in November 2014 it was extended through May 16, 2015. Since the signing of the MOU, management of Provectus and senior personnel at Sinopharm-CSIPI and Sinopharm A-THINK have held numerous conference calls, have met face-to-face in both China and the US, and Chinese scientists on staff at Sinopharm have discussed in person PV-10 and its clinical results with the lead investigators at St. Luke's University Hospital and Health Network and Moffitt Cancer Center.

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 Clinical Data from Phase 1 Study for Cancers of the Liver

Provectus Biopharmaceuticals, Inc. announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology’s 17th World Congress on Gastrointestinal Cancer, is scheduled for July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.

Provectus Biopharmaceuticals, Inc. - Special Call

To discuss on quarterly business update and provide a business update on PV-10 and PH-10

Similar Private Companies By Industry

Company Name Region
PL Developments, Inc. United States
OsteoGeneX Inc. United States
Eye-Pharma, LLC United States
Synergia Pharma, Inc. United States
LifeGuard Health, LLC United States

Recent Private Companies Transactions

Private Placement
October 15, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Provectus Biopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at